GSK’s Mekinist/Tafinlar Combo Pushes The Price Bar
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK’s MEK inhibitor Mekinist and BRAF inhibitor Tafinlar are the first two targeted therapies approved in combination for the treatment of metastatic melanoma. The prices of the separate components are below other comparable oncology launches, but the combination will push the price to over $17,115 for a month of treatment.